SCHEMBL22499263

SCHEMBL22499263

CCOC(=O)c1cc(=O)c2c(F)cccc2o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.55
MAPK1 P28482 1/20 0.55
MAOB P27338 2/20 0.54
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 2/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SLC2A1 P11166 1/20 0.47
ATM Q13315 1/20 0.46
MAPT P10636 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
AR P10275 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116712 0.85 NPC1 (0.60) AKR1B1MAPK1MAOBTSHRSLC2A1
SCHEMBL4251548 0.85 AKR1B1 (0.56) AKR1B1MAPK1MAOBKMT2AKDM4E
SCHEMBL21218235 0.84 AKR1B1 (0.55) AKR1B1MAPK1MAOBKMT2AKDM4E
SCHEMBL16693136 0.83 MAOB (0.53) AKR1B1MAOBKMT2AKDM4EALDH1A1
SCHEMBL30224991 0.83 MAOB (0.56) AKR1B1MAPK1MAOBKMT2AKDM4E
SCHEMBL10464658 0.83 MAPK1 (0.57) AKR1B1MAPK1MAOBKMT2AKDM4E
SCHEMBL5279035 0.83 MAOB (0.56) AKR1B1MAPK1MAOBKMT2AKDM4E
SCHEMBL26645927 0.81 NMT2 (0.54) AKR1B1MAPK1MAOBKMT2ASLC2A1
SCHEMBL19744184 0.80 AKR1B1 (0.54) AKR1B1MAPK1MAOBKMT2ASLC2A1
SCHEMBL4247906 0.80 AKR1B1 (0.51) AKR1B1MAPK1MAOBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 CN disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 AKR1B1 1529/4885MAPK1 2959/4885MAOB 898/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT AKR1B1 1076/4885MAPK1 3970/4885MAOB 1204/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 AKR1B1 1529/4885MAPK1 2959/4885MAOB 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.